Literature DB >> 25653436

Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions.

Kaitlin Anstett1, Thibault Mesplede2, Maureen Oliveira2, Vincent Cutillas1, Mark A Wainberg3.   

Abstract

The new integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) displays limited cross-resistance with older drugs of this class and selects for the R263K substitution in treatment-experienced patients. We performed tissue culture selections with DTG, using viruses resistant to older INSTIs and infectivity and resistance assays, and showed that the presence of the E92Q or N155H substitution was compatible with the emergence of R263K, whereas the G140S Q148R, E92Q N155H, G140S, Y143R, and Q148R substitutions were not.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25653436      PMCID： PMC4442391          DOI： 10.1128/JVI.03485-14

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  13 in total

1.  Isolation of drug-resistant mutant HIV variants using tissue culture drug selection.

Authors:  Maureen Oliveira; Bluma G Brenner; Mark A Wainberg
Journal:  Methods Mol Biol       Date:  2009

2.  Development of antiretroviral drug resistance.

Authors:  Mark A Wainberg; Gerasimos J Zaharatos; Bluma G Brenner
Journal:  N Engl J Med       Date:  2011-08-18       Impact factor: 91.245

3.  Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.

Authors:  Peter K Quashie; Thibault Mesplède; Ying-Shan Han; Maureen Oliveira; Diane N Singhroy; Tamio Fujiwara; Mark R Underwood; Mark A Wainberg
Journal:  J Virol       Date:  2011-12-28       Impact factor: 5.103

Review 4.  Rationale and uses of a public HIV drug-resistance database.

Authors:  Robert W Shafer
Journal:  J Infect Dis       Date:  2006-09-15       Impact factor: 5.226

5.  Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors.

Authors:  Maureen Oliveira; Thibault Mesplède; Peter K Quashie; Daniela Moïsi; Mark A Wainberg
Journal:  AIDS       Date:  2014-03-27       Impact factor: 4.177

6.  Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.

Authors:  Isabelle Hardy; Bluma Brenner; Peter Quashie; Réjean Thomas; Christos Petropoulos; Wei Huang; Daniela Moisi; Mark A Wainberg; Michel Roger
Journal:  J Antimicrob Chemother       Date:  2014-10-03       Impact factor: 5.790

7.  Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012.

Authors:  Christopher B Hurt; Joseph Sebastian; Charles B Hicks; Joseph J Eron
Journal:  Clin Infect Dis       Date:  2013-10-21       Impact factor: 9.079

8.  Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure.

Authors:  Thibault Mesplède; Peter K Quashie; Nathan Osman; Yingshan Han; Diane N Singhroy; Yolanda Lie; Christos J Petropoulos; Wei Huang; Mark A Wainberg
Journal:  Retrovirology       Date:  2013-02-22       Impact factor: 4.602

9.  Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.

Authors:  Joseph J Eron; Bonaventura Clotet; Jacques Durant; Christine Katlama; Princy Kumar; Adriano Lazzarin; Isabelle Poizot-Martin; Gary Richmond; Vincent Soriano; Mounir Ait-Khaled; Tamio Fujiwara; Jenny Huang; Sherene Min; Cindy Vavro; Jane Yeo
Journal:  J Infect Dis       Date:  2012-12-07       Impact factor: 5.226

10.  The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness.

Authors:  Melissa Wares; Thibault Mesplède; Peter K Quashie; Nathan Osman; Yingshan Han; Mark A Wainberg
Journal:  Retrovirology       Date:  2014-01-17       Impact factor: 4.602
View more
  18 in total

1.  Differential assembly of Rous sarcoma virus tetrameric and octameric intasomes is regulated by the C-terminal domain and tail region of integrase.

Authors:  Sibes Bera; Krishan K Pandey; Hideki Aihara; Duane P Grandgenett
Journal:  J Biol Chem       Date:  2018-09-05       Impact factor: 5.157

2.  Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.

Authors:  Robert W Shafer
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 5.226

3.  HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity.

Authors:  Kaitlin Anstett; Bluma Brenner; Thibault Mesplède; Mark A Wainberg
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

4.  Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity.

Authors:  Kaitlin Anstett; Vincent Cutillas; Robert Fusco; Thibault Mesplède; Mark A Wainberg
Journal:  J Antimicrob Chemother       Date:  2016-04-15       Impact factor: 5.790

5.  Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.

Authors:  Said A Hassounah; Yannan Liu; Peter K Quashie; Maureen Oliveira; Daniela Moisi; Bluma G Brenner; Paul A Sandstrom; Thibault Mesplède; Mark A Wainberg
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

6.  Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.

Authors:  Said A Hassounah; Ahmad Alikhani; Maureen Oliveira; Simrat Bharaj; Ruxandra-Ilinca Ibanescu; Nathan Osman; Hong-Tao Xu; Bluma G Brenner; Thibault Mesplède; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

7.  Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.

Authors:  Emmanuel Ndashimye; Mariano Avino; Fred Kyeyune; Immaculate Nankya; Richard M Gibson; Eva Nabulime; Art F Y Poon; Cissy Kityo; Peter Mugyenyi; Miguel E Quiñones-Mateu; Eric J Arts
Journal:  AIDS Res Hum Retroviruses       Date:  2018-02-26       Impact factor: 2.205

Review 8.  Multifunctional facets of retrovirus integrase.

Authors:  Duane P Grandgenett; Krishan K Pandey; Sibes Bera; Hideki Aihara
Journal:  World J Biol Chem       Date:  2015-08-26

9.  Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.

Authors:  Bluma G Brenner; Réjean Thomas; José Luis Blanco; Ruxandra-Ilinca Ibanescu; Maureen Oliveira; Thibault Mesplède; Olga Golubkov; Michel Roger; Federico Garcia; Esteban Martinez; Mark A Wainberg
Journal:  J Antimicrob Chemother       Date:  2016-03-29       Impact factor: 5.790

10.  The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors.

Authors:  Hanh T Pham; Lydia Labrie; Ingeborg E A Wijting; Said Hassounah; Ka Yee Lok; Inna Portna; Mark E Goring; Yingshan Han; Cynthia Lungu; Marchina E van der Ende; Bluma G Brenner; Charles A Boucher; Bart J A Rijnders; Jeroen J A van Kampen; Thibault Mesplède; Mark A Wainberg
Journal:  J Infect Dis       Date:  2018-07-24       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.